{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:45:06Z","timestamp":1776062706733,"version":"3.50.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The HIV vaccine field has swung between humoral-based to cell-mediated approaches; however the consensus has evolved toward the understanding that an induction of both may be important for optimal protection. HLA class I molecules present viral epitopes to initiate CD8+ T cell responses to HIV-infected cells while broadly neutralizing antibodies (bNAbs) primarily target free virions. In this study, we systematically compared HIV-1 ENV CD8+ T cell epitopes restricted by two HLA class I alleles associated with divergent HIV-1 infection outcomes with bNAb epitopes reported to date in the literature. To our knowledge, this represents one of the first attempts of examining and reconciling the targets of cellular and humoral immunity in the context of differing HIV infection outcomes. Among 1820 peptides overlapping HIV-1 clades A and D ENV, A*01:01 (associated with slower HIV-1 acquisition) bound to 20, while B*07:02 (associated with susceptibility) bound to 64. No significant differences in affinity or off-rate were noted between A*01:01 and B*07:02 epitopes, and a higher proportion of A*01:01 epitopes are located within constant ENV regions than B*07:02 epitopes (C:V ratio 3:1 versus 2:1, respectively). Of the epitopes and variants discovered in this study, 7 of 20 (35%) A*01:01 and 11 of 64 (17%) B*07:02 binders overlapped with known bNAb target sites. All CD8+ T cell epitopes overlapping CD4-binding site clusters were also bNAbs targets. Notably, all A*01:01 T cell epitopes overlapping bNAb epitopes were within conserved ENV regions, and all but one involved glycan-dependent bNAb binding. The epitope landscape analysis therefore showed the allele associated with slower HIV-1 infection rates presents a narrower repertoire of ENV CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell epitopes, that preferentially overlaps bNAb target sites, consistent with coordinated immune targeting between cellular and humoral arms of immunity.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1786452","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:46:25Z","timestamp":1776059185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing CD8+ T cell ENV epitopes of two HLA class I alleles associated with different outcomes of HIV-1 infection with broadly neutralizing antibodies epitope targets discovered to date"],"prefix":"10.3389","volume":"17","author":[{"given":"Akhil","family":"Ramdoyal","sequence":"first","affiliation":[{"name":"Max Rady College of Medicine, University of Manitoba","place":["Winnipeg, MB, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Daniuk","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory Branch, Public Health Agency of Canada","place":["Winnipeg, MB, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Were","family":"Omange","sequence":"additional","affiliation":[{"name":"Biomarker Sciences, Gilead Sciences","place":["Foster City, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Kimani","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba","place":["Winnipeg, MB, Canada"]},{"name":"Department of Medical Microbiology, University of Nairobi","place":["Nairobi, Kenya"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma","family":"Luo","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory Branch, Public Health Agency of Canada","place":["Winnipeg, MB, Canada"]},{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba","place":["Winnipeg, MB, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","article-title":"Global HIV & AIDS statistics \u2014 Fact sheet","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0313","article-title":"Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals","volume":"27","author":"Young","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/qad.0b013e32830e6d6d","article-title":"Post-step modifications for research on HIV vaccines","volume":"23","author":"Corey","year":"2009","journal-title":"AIDS (London England)"},{"key":"B4","article-title":"Top stories of 2008. Crash and burn of HIV vaccine candidates","volume":"21","author":"Del Rio","year":"2009","journal-title":"AIDS Clin Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1055\/s-0028-1124057","article-title":"HIV-AIDS 2008: the year in review","volume":"5","author":"Amari El","year":"2009","journal-title":"Rev Med Suisse"},{"key":"B6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0028-1124057","article-title":"The HIV vaccine is coming\u2014but when","volume":"134","author":"Gross","year":"2009","journal-title":"Dtsch Med Wochenschr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.05721-11","article-title":"For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection","volume":"86","author":"Luo","year":"2012","journal-title":"J Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002251","article-title":"Extremely high mutation rate of HIV-1 in vivo","volume":"13","author":"Cuevas","year":"2015","journal-title":"PloS Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4187","article-title":"Determinants of HIV-1 broadly neutralizing antibody induction","volume":"22","author":"Rusert","year":"2016","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005369","article-title":"Broadly neutralizing antibody responses in a large longitudinal Sub-Saharan HIV primary infection cohort","volume":"12","author":"Landais","year":"2016","journal-title":"PloS Pathog"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)12269-2","article-title":"Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya","volume":"348","author":"Fowke","year":"1996","journal-title":"Lancet"},{"key":"B12","first-page":"1","article-title":"A review of the role of the human leukocyte antigen (HLA) system as a host immunogenetic factor influencing HIV transmission and progression to AIDS","volume-title":"HIV Molecular Immunology","author":"Trachtenberg","year":"2001"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1711.2006.01455.x","article-title":"Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya","volume":"84","author":"Alimonti","year":"2006","journal-title":"Immunol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/tan.12051","article-title":"HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort","volume":"81","author":"Peterson","year":"2013","journal-title":"Tissue Antigens"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101475","article-title":"Influence of HLA class I haplotypes on HIV-1 seroconversion and disease progression in Pumwani sex worker cohort","volume":"9","author":"Sampathkumar","year":"2014","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0952-7915(95)80033-6","article-title":"Chemistry of peptides associated with MHC class I and class II molecules","volume":"7","author":"Rammensee","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/s41587-024-02289-x","article-title":"A vaccine strategy for inducing broadly neutralizing antibodies against HIV","volume":"42","author":"Marchal","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5371.1884","article-title":"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens","volume":"280","author":"Wyatt","year":"1998","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000479549.21614.5a","article-title":"HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13530","article-title":"The HIV glycan shield as a target for broadly neutralizing antibodies","volume":"282","author":"Doores","year":"2015","journal-title":"FEBS J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.029","article-title":"HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure","volume":"48","author":"Kwong","year":"2018","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031869","article-title":"Identification of cryptic MHC I\u2013restricted epitopes encoded by HIV-1 alternative reading frames","volume":"199","author":"Cardinaud","year":"2004","journal-title":"J Exp Med"},{"key":"B24","article-title":"ENV CTL\/CD8+ Epitope Map","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199002000-00007","article-title":"HIV infection among lower socioeconomic strata prostitutes in Nairobi","volume":"4","author":"Simonsen","year":"1990","journal-title":"Aids"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2024.12.10.627672","article-title":"Molecular evolutionary genetics analysis version 12 for adaptive and green computing","volume":"41","author":"Kumar","year":"2024","journal-title":"Mol Biol Evol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.5.4393-4403.1999","article-title":"Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya","volume":"73","author":"Neilson","year":"1999","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049797","article-title":"HIV-1 clade D is associated with increased rates of CD4 decline in a Kenyan cohort","volume":"7","author":"McKinnon","year":"2012","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003191","article-title":"Genetic analysis of HIV-1 subtypes in Nairobi, Kenya","volume":"3","author":"Khoja","year":"2008","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxn063","article-title":"Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4","volume":"20","author":"Shingler","year":"2008","journal-title":"Int Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-450-6_26","article-title":"Identification of human MHC class I binding peptides using the iTOPIA- epitope discovery system","volume":"524","author":"Wulf","year":"2009","journal-title":"Methods Mol Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.11.002","article-title":"Identification and characterization of HLA-A*0301 epitopes in HIV-1 gag proteins using a novel approach","volume":"352","author":"Semeniuk","year":"2010","journal-title":"J Immunol Methods"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082805","article-title":"Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses","volume":"8","author":"Yi","year":"2013","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973652","article-title":"Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody","volume":"266","author":"Burton","year":"1994","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature05580","article-title":"Structural definition of a conserved neutralization epitope on HIV-1 gp120","volume":"445","author":"Zhou","year":"2007","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008805","article-title":"Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals","volume":"5","author":"Corti","year":"2010","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068863","article-title":"The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody","volume":"8","author":"Balla-Jhagjhoorsingh","year":"2013","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18594","article-title":"Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans","volume":"9","author":"Julien","year":"2013","journal-title":"PloS Pathog"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083182","article-title":"Antibody domain exchange is an immunological solution to carbohydrate cluster recognition","volume":"300","author":"Calarese","year":"2003","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.11.6642-6647.1993","article-title":"A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1","volume":"67","author":"Muster","year":"1993","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/08892220152741450","article-title":"A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1","volume":"17","author":"Stiegler","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.cell.2019.06.030","article-title":"Antibody lineages with vaccine-induced antigen-binding hotspots develop broad HIV neutralization","volume":"178","author":"Kong","year":"2019","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9998","DOI":"10.1128\/jvi.05045-11","article-title":"Analysis of a clonal lineage of HIV-1 envelope V2\/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors","volume":"85","author":"Bonsignori","year":"2011","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3963","article-title":"Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies","volume":"21","author":"Bhiman","year":"2015","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.04.009","article-title":"Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers","volume":"40","author":"Falkowska","year":"2014","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.22.10892-10905.2001","article-title":"Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41","volume":"75","author":"Zwick","year":"2001","journal-title":"J Virol"},{"key":"B54","volume-title":"Structure of full-length, fully glycosylated, non-modified HIV-1 gp160 bound to PG16 Fab [PDB6WU]","author":"Pan","year":"2020"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"Gottardo","year":"2013","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102756","article-title":"The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope","volume":"188","author":"De Souza","year":"2012","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0103","article-title":"The Thai phase III HIV-1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120","volume":"28","author":"Karasavvas","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081227","article-title":"The relative positioning of B and T cell epitopes\u00a0drives\u00a0immunodominance","volume":"10","author":"Biavasco","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.070","article-title":"HLA based selection of epitopes offers a potential window of opportunity for vaccine design against HIV","volume":"35","author":"Sundaramurthi","year":"2017","journal-title":"Vaccine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12484","article-title":"Identification and specificity of broadly neutralizing antibodies against HIV","volume":"275","author":"McCoy","year":"2017","journal-title":"Immunol Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006498107","article-title":"Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens","volume":"107","author":"Doores","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2000260117","article-title":"Visualization of the HIV-1 ENV glycan shield across scales","volume":"117","author":"Berndsen","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.01.052","article-title":"Structural insights on the role of antibodies in HIV-1 vaccine and therapy","volume":"156","author":"West","year":"2014","journal-title":"Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12504","article-title":"Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies","volume":"275","author":"Borrow","year":"2017","journal-title":"Immunol Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:46:26Z","timestamp":1776059186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2026.1786452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1786452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1786452"}}